QIoTrak: Redefining Post-Surgical Recovery
Welcome to the private investor overview for QIoTrak, a world-first connected monitoring solution for surgical drains. Co-developed with the Mayo Clinic (USA) and Royal Papworth Hospital (UK), QIoTrak is set to transform how hospitals manage recovery — enabling safe discharge, remote oversight, and predictive intervention.
The Problem
Over 12.8 million post-surgical drains are used annually in the US alone, with millions more globally. Monitoring these drains typically requires extended hospital stays, driving up healthcare costs and straining resources. Hospitals need a scalable, cost-effective solution to support earlier discharge while maintaining clinical safety.
Our Solution
- Non-invasive clip-on device for standard surgical drains
- Real-time acoustic monitoring of fluid, air, and blood flow
- Integrated patient-reported data: SpO₂, pain, meds, wound healing
- Secure doctor-only web portal with alerts and trend tracking
- Reduces inpatient bed-days by an average of 3 to 5 days per case
Where We Are Now
- TRL6 prototype complete (as shown)
- Advancing to TRL9 via pilot deployments with Mayo Clinic (USA) and Royal Papworth Hospital (UK)
- Backed by public innovation grants in UK
- Active investor discussions underway – limited equity available in current round
Market Focus & Revenue Potential
QIoTrak is built to serve five high-volume surgical recovery sectors, representing over 5.1 million drain uses per year in the US alone. Our target is a modest 1% market share, generating:
- $164M in recurring DaaS revenue (based on $300/month/device, 3-year terms)
- $492M total contract value (TCV)
- With a net profit margin of 86%
This model is underpinned by hospital savings on bed-days, reduced readmissions, and improved outcomes — making QIoTrak a win for both care and cost
Funding Update
We are raising $3.9 million to support scale-up, certification, and launch. To date, we have secured $1.58 million in committed funding from institutional and government sources.
Interested in Investing?
We are currently raising funds to support commercialisation and market entry. If you’re looking to invest in a validated, high-potential MedTech platform with strong global clinical partners, contact:
Frank Quinn, CEO
